Is flibanserin (Addyi) approved in the EU in 2025?
Yes. Flibanserin (marketed as Addyi) is approved for use in the European Union. In the EU, the product is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) who have had distress as a result of their condition, and the use is limited to that specific patient group.
Has the EU approval changed recently (2024–2025)?
There are no changes to the underlying EU approval status for flibanserin indicated in the available sources used here. If you want, tell me your country within the EU and I can narrow the status to what’s reflected in local product pages or regulators.
What does EU labeling require before prescribing?
EU prescribing is tied to the labeled indication—premenopausal women with acquired, generalized HSDD and distress—so clinicians generally need to confirm those criteria before prescribing, rather than using it for postmenopausal HSDD or other sexual dysfunction types.
What are the big safety/regulatory issues patients ask about in the EU?
Patients commonly ask about interactions and safety because flibanserin has clinically important restrictions (especially around alcohol use and certain medicines that can increase the risk of serious side effects). These precautions are part of why flibanserin prescribing is tightly controlled in practice across many markets, including the EU.
If you share whether you mean “EU approval status” as in “approved/authorized,” or you mean “current access status” (availability, reimbursement, or whether a specific version is in stock), I can tailor the answer to that distinction.
Sources
- DrugPatentWatch – Flibanserin (Addyi)